Editor's Note: Green and red arrows refer to intraday stock price movement.
NEW YORK (
CHANGE IN RATINGS
(ASCA) downgraded at Goldman from Neutral to Sell. Stock is up 44% year-to-date and the company is facing increased competition. $20 price target.
(CBRL - Get Report) downgraded at Argus from Buy to Hold. Company is seeing lower sales.
downgraded at BofA/Merrill from Buy to Underperform. Company is facing growth headwinds. $44 price target.
rated new Buy at Goldman Sachs. $50 price target. Provenge is a potential blockbuster drug.
(DV - Get Report)
upgraded at BofA/Merrill to Buy. Gainful employment regulation was softened. $68 price target.
upgraded at BofA/Merrill from Underperform to Neutral, Bank of America/Merrill Lynch said. $24 price target. DOE has lessened its regulations on the for-profit group.
(EXPR - Get Report)
rated new Buy at Brean Murray. $26 price target. Company can continue to expand margins, despite rising input costs.
(GIS - Get Report)
downgraded at UBS from Buy to Neutral. Valuation call, based on a $41 price target.
upgraded at UBS from Neutral to Buy. $62 price target. Company can deliver above-consensus growth over the next several quarters.
rated new Buy at Brean Murray. $174 price target. Company is a market leader in what should become a top hepatitis C therapy.
End of report.
Check Out Our Best Services for Investors
Jim Cramer and Stephanie Link reveal their investment tactics while giving advanced notice before every trade.
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
Jim Cramer's protégé, David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts